Jiangsu Yarong Medicine Technology Co., Ltd. (hereinafter referred to as 'Yarong Medicine') was successfully listed on January 7, 2022, with an issue price of 22.98 yuan per share. A total of 110 million shares were issued, raising a financing amount of 2.07 billion yuan.
Frost & Sullivan is a global innovative pharmaceutical company focusing on urological and reproductive system tumors and other major diseases, dedicated to launching world-leading drugs in the therapeutic areas where it specializes. In addition, Frost & Sullivan is a winner in differentiated competition within medical niche segments, avoiding homogeneous competition in major disease areas and establishing a deep pipeline of research products in the urological and reproductive fields. Among them, Frost & Sullivan has taken non-muscle-invasive bladder cancer (NMIBC) as its first key market, constructing an advantageous product portfolio covering NMIBC. Two core product pipelines, APL-1202 and APL-1702, are already in Phase III or pivotal clinical trials. Frost & Sullivan has long been concerned about the global and Chinese biopharmaceutical industries, publishing a large number of research reports, which are widely cited in the prospectuses of leading ChiNext-listed companies, helping clients accelerate growth.
Overall development overview of the pharmaceutical industry
Under the combined influence of factors such as accelerating aging, increased social healthcare expenditures, and rising R&D investment, the global pharmaceutical market has maintained stable growth in the past. The global pharmaceutical market size grew from $1,153 billion in 2016 to $1,298 billion in 2020, with a compound annual growth rate of 3.0% from 2016 to 2020. It is estimated that by 2025, the global pharmaceutical market size will reach $1,681 billion, with a compound annual growth rate of 5.3% from 2020 to 2025.
Global pharmaceutical market size by drug type, 2016 - 2030E
Source: Frost & Sullivan report
Under the combined influence of steady economic development and increasing medical demand, China's pharmaceutical market size increased from 1,329.4 billion yuan in 2016 to 1,448 billion yuan in 2020, with a compound annual growth rate of 2.2%. It is estimated that by 2025, China's pharmaceutical market size will reach 2,287.3 billion yuan, with a compound annual growth rate of 9.6% from 2020 to 2025.
China's pharmaceutical market size by drug type, 2016-2030E
Source: Frost & Sullivan report
Overview of the Urological and Reproductive Drug Market
The urinary system and reproductive system are important systems responsible for human excretion and the reproduction of offspring, respectively. The urinary system maintains the stability of the internal environment by generating and excreting urine. The anatomical structure of the human urinary system mainly includes: kidneys, bladder, ureters, and urethra. The reproductive system is a collective term for the organs involved in the reproduction of offspring and the continuation of the species. In males, the main sex organ is the testes, with accessory organs including the vas deferens, accessory glands, and external genitalia. In females, the main sex organ is the ovaries, with accessory organs including the fallopian tubes, uterus, vagina, and vulva.
Common urogenital system diseases can be divided into tumors and non-tumorous diseases. Tumor diseases are classified according to the location of the tumor (i.e., different affected organs), which can be divided into urological tumors and genitourinary tumors. Non-tumorous diseases are classified according to the main subspecialties, which can be divided into infectious and inflammatory diseases and other non-tumorous diseases.
Male urogenital system tumors are a collection of tumors affecting the urinary and male reproductive systems, including three major types with high incidence rates: prostate cancer, bladder cancer, and kidney cancer, as well as less common tumors such as testicular cancer and penile cancer. Among female reproductive system tumors, cervical cancer, breast cancer, endometrial cancer, and ovarian cancer are the main components of malignant tumors.
Globally, drugs for urogenital system diseases have a huge market. The global market size for urogenital system cancers reached $342 billion in 2016, grew to $541 billion in 2020, with a compound annual growth rate of 12.2% from 2016 to 2020. The global urogenital system cancer market will continue to grow, expected to reach $98.6 billion by 2025 and $1499 billion by 2030. The compound annual growth rate from 2020 to 2025 is expected to be 12.7%, and the projected compound annual growth rate from 2025 to 2030 will reach 8.7%.
Global market size of urological and reproductive system cancers, 2016 - 2030E
Source: Frost & Sullivan report
The market scale of urological and reproductive system cancers in China reached 348 billion yuan in 2016, increased to 540 billion yuan by 2020, with a compound annual growth rate of 11.6% from 2016 to 2020. The urological and reproductive system cancer market in China will continue to grow, expected to reach 1190 billion yuan by 2025 and 1987 billion yuan by 2030. The compound annual growth rate from 2020 to 2025 is expected to be 17.1%, and the projected compound annual growth rate from 2025 to 2030 will reach 10.8%.
Market Size of Urological and Reproductive System Cancers in China, 2016 - 2030E
Source: Frost & Sullivan report
Frost & Sullivan, integrating 61 years of global consulting experience, has dedicated 24 years to serving the booming Chinese market. With a global perspective, we help clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The healthcare industry is one of Frost & Sullivan's core areas of focus. Over the past seventeen years, the Frost & Sullivan healthcare team has provided financing and financial advisory services, IPO industry advice, strategic consulting, management consulting, and other services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies. Successful listings include: Bexcellence (2185.HK), Yonghe Medical (2279.HK), Kailaiying (6821.HK), Beihai Kangcheng (1228.HK), Gushengtang (2273.HK), Yingtong Technology (2251.HK), Clover Biotech (2197.HK), Minimally Invasive Robotics (2252.HK), Harmony Kampan (2256.HK), Kunbo Medical (2216.HK), Xianruida (6669.HK), Kangsheng Global (9960.HK), Yimaitong (2192.HK), Tengsheng Bopai (2137.HK), CanSino (2162.HK), Chaoyu Ophthalmology (2219.HK), Guichuang Tongqiao (2190.HK), Hehuang Medicine (0013.HK), Koi Pharmaceutical (2171.HK), Zhaoke Ophthalmology (6622.HK), Nature Pharmaceuticals (UPC.NASDAQ), Saiseng Pharmaceutical (6600.HK), Zhaoyan New Drugs (6127.HK), Novogene Health (6606.HK), Tianyan Pharmaceuticals (ADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao (2161.HK), Minimally Invasive Xin Tong (2160.HK), Ruili Medical Beauty (2135.HK), Jiake Pharmaceutical (1167.HK), Hebo Medicine (2142.HK), JD Health (6618.HK), Deqi Medicine (6996.HK), Rongchang Biotech (9995.HK), WuXi AppTec (2126.HK), SonoBIO (2096.HK), Yunding Newray (1952.HK), Jiahe Biotech (6998.HK), Zai Ding Medicine (9688.HK), Ocular Biotech (1477.HK), Yongtai Biotech (6978.HK), Haipu Pharmaceutical (9989.HK), Keping Pharmaceutical (9939.HK), Peijia Medical (9996.HK), Kangfang Biotech (9926.HK), Nuo Cheng Jian Hua (9969.HK), Tianjing Biotech (IMAB.NASDAQ), Kanglong Chemical (3759.HK), China Antibody (3681.HK), Dongyao Pharmaceutical (1875.HK), Yasheng Medicine (6855.HK), Fuhong Hanlin (2696.HK), Hansoh Pharmaceutical (3692.HK), Mabotech (2181.HK), Fangda Holdings (1521.HK), Via Biotech (1873.HK), CStone Pharmaceuticals (2616.HK), Junshi Biosciences (1877.HK), WuXi AppTec (2359.HK), Innovent Biologics (1801.HK), Hailong Medicine (2552.HK), BeiGene (6160.HK), Gilead Sciences (1672.HK), WuXi Biologics (2269.HK), China Resources Medicine (3320.HK), Jacobus Burchen Research Pharmaceutical (2633.HK), Hehuang China Medicine (HCM.NASDAQ), GSK Biologics (1548.HK), BBI Life Sciences (1035.HK), etc. In terms of the number of listed projects, the Frost & Sullivan healthcare team maintains an absolute leading position in Hong Kong healthcare IPOs, continuously occupying more than 90% of the market share from 2018 to 2021.
Since the listing of the first batch of companies on the Sci-tech Innovation Board in July 2019, Frost & Sullivan reports have been widely cited in the prospectuses of leading Sci-tech Innovation Board listed companies in the industry. These include: BeiGene (688235.SH), Harvestime Biologics (688246.SH), Dicang Pharmaceuticals (688192.SH), Novogene (688105.SH), Chengda Biology (688739.SH), GenoKee (688728.SH), Huaxi Biosciences (688363.SH), Junshi Biosciences (688180.SH), Zhejiang Genomics & Biotechnology Co., Ltd. (688266.SH), BeiGene-Thera Oncology (688177.SH), Shenzhou Cells (688520.SH), etc. They are considered the most powerful, professional, and influential industry research institutions in the sector. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's healthcare industry, and build a healthy future.
Recommended Reading
Frost & Sullivan helps Saisun Pharma successfully go public in Hong Kong (6600.HK)
38. Frost & Sullivan assists Zai Lab to successfully list on the Hong Kong Stock Exchange (9688.HK)
46. Frost & Sullivan assisted Tianjing Biology in successfully going public in the US (IMAB.NASDAQ)
